Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM(SM) registry

BACKGROUND: Immune related adverse events (irAEs) are associated with immunotherapy for cancer and while results suggest improvement in tumor control and overall survival in those experiencing irAEs, the long-term impact is debated. We evaluated irAE reports related to high dose interleukin-2 therap...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:J Immunother Cancer
Główni autorzy: Curti, Brendan, Daniels, Gregory A., McDermott, David F., Clark, Joseph I., Kaufman, Howard L., Logan, Theodore F., Singh, Jatinder, Kaur, Meenu, Luna, Theresa L., Gregory, Nancy, Morse, Michael A., Wong, Michael K. K., Dutcher, Janice P.
Format: Artigo
Język:Inglês
Wydane: BioMed Central 2017
Hasła przedmiotowe:
Research Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5735508/
https://ncbi.nlm.nih.gov/pubmed/29254506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0307-5
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy